Start Your Search
MA15 - Usage of Computer and Molecular Analysis in Treatment Selection and Disease Prognostication (ID 141)
- Event: WCLC 2019
- Type: Mini Oral Session
- Track: Pathology
- Presentations: 1
- Now Available
MA15.09 - PD-L1 Status in Relation with Non-Small Cell Lung Cancer Major Subtypes, Differentiation, Molecular Profiling and Smoking History (Now Available) (ID 2874)
15:45 - 17:15 | Author(s): Stephanie Snow
Continued advances in lung cancer precision medicine have allowed targeted therapies based on an individual tumor’s genetic makeup. Recent advances in immune therapy based on immune checkpoint inhibitors have provided additional promising results. Currently, the majority of lung cancer mutational data available in the literature are from advanced stage non-small cell lung cancer. Mutational data from early stage lung cancer patients is limited. There is also limited data on PD-L1 tumor status is relation to mutational status along with other pathological and clinical characteristics. In this study, we evaluated these issues in 871 cases of surgically resected lung cancer.Method
Multiplexed molecular profiling in 871 surgically resected lung cancer specimens was performed. A panel of genes including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK was tested. Tumor PD-L1 status was also evaluated by immunohistochemistry using pharmDx22C3. PD-L1 status was measured by tumor proportional score (TPS): <1%, 1-49% and ≥50% tumor cell positivity. Correlations between PD-L1 and gene mutation status, smoking history, histological grade, gender and age of paraffin embedded blocks were analyzed.Result
This cohort includes adenocarcinoma (68%), squamous cell carcinoma (SCC) (22%) and other subtypes (10%). The average age is 67. Females account for 52%. A positive smoking history was present in 93%. Well differentiated tumors (G1) account for 11%, moderately differentiated (G2) 37% and poorly and undifferentiated (G3) 52%. EGFR mutations were identified in 7.4% and KRAS mutations in 31.7%. TPS <1% accounted for 48.8%, 1-49% for 34.6% and ≥50% for 16.5%.
There was no statistically significant difference in PD-L1 TPS between histological subtypes or gender. Significantly more G1 tumors had a TPS <1% (76.7%) compared to G2 (57.4%, p=0.0013) and G3 tumors (41.8%, p<0.0001). Fewer G1 tumors had a TPS 1-49% (20.9%) than G2 (34.1%, p=0.015) and G3 (35.2%, p=0.01) tumors. G3 tumors were more likely to have a TPS ≥50% (24.6%) than G1 (2.3%, p<0.0001) and G2 (7.63%, p<0.0001) tumors. Never smokers were more likely to have a TPS <1% (71.1% vs 50.6%, p=0.04) and less likely to have a TPS ≥50% (5.8% vs 16.5%, p=0.04). Tumors with EGFR mutation were more likely to have a TPS <1% than those without EGFR mutation (70.7% vs 47.3%, p=0.0003) and less likely to have a TPS 1-49% (20.0 vs 35.5%, p=0.011). Tumors with KRAS mutations were less likely to have a TPS <1% (36.6% vs 54.9%, p<0.0001) and more likely to have a TPS 1-49% (40.6% vs 31.5%, p=0.0086) and ≥50% (22.8% vs 13.6%, p=0.0007). PD-L1 IHC performed on blocks stored for 2 years or longer had a statistically significant higher rate of TPS <1% compared to blocks stored for less than 2 years.Conclusion
This study provides information relating to the relationship between PD-L1 levels and tumor molecular profile, histological grade and patient demographics. Additionally, we raise the possibility of false negatives on IHC performed for PD-L1 on paraffin embedded blocks stored for 2 years or more.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.